Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
thdb.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

3

Partners & Customers

2

About Tonghua Dongbao Pharmaceutical

Tonghua Dongbao Pharmaceutical (600867.SH) is a China-based company principally engaged in the manufacture and distribution of pharmaceuticals and construction materials.

Tonghua Dongbao Pharmaceutical Headquarter Location

Tonghua, Jilin,

China

+86-435-5088025

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Tonghua Dongbao Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Tonghua Dongbao Pharmaceutical Rank

Latest Tonghua Dongbao Pharmaceutical News

Sam Chun Dang explains licensing talk with Chinese partner for a year. Why?

May 4, 2022

바로가기 기자명 Kim Chan-hyuk 닫기 Sam Chun Dang Pharm has been clarifying the discussion with a Chinese pharmaceutical firm over licensing out a diabetic drug candidate repeatedly for a year. Attention is on whether the two will ink a final deal and when it will happen. “We are discussing a deal with China’s Tonghua Dongbao Pharmaceutical based on a draft agreement,” the Kosdaq-listed company said in a public filing on Tuesday. “We will file a disclosure again when related matters are confirmed specifically or within three months.” In the latest disclosure, Sam Chung Dang Pharm said a human pilot study of oral insulin ended in Korea on April 15. Later, the company will get the final study report from a contract research organization (CRO). The announcement aimed to clarify a local news report, released on May 3, 2021, titled, “Sam Chun Dang Pharm pushes to invest 200 billion won ($158.7 million) in oral insulin.” Since the news report, Sam Chung Dang Pharm filed clarifications seven times over a year. Immediately after the news report, Sam Chun Dang Pharm said on May 4, 2021, that it signed a letter of intent (LOI) for strategic cooperation with a Chinese partner company in November 2020. Later, the Korean firm confirmed the name of the Chinese company, Tonghua Dongbao Pharmaceutical. Sam Chun Dang Pharm also said that it delivered a term sheet and toxicity test results to the Chinese firm through additional filings. As a result, it clinched a term sheet where the Chinese partner will cover all the costs for clinical trials and approve the oral insulin and GLP-1 analogs in China. Sam Chun Dang Pharm said it signed an agreement with a clinical site and a CRO for a human pilot study and disclosed the status of its pipelines in development, too. Repeated public disclosures indicate that Sam Chun Dang Pharm and Tonghua Dongbao Pharmaceutical have been negotiating over the draft of the licensing deal since December 2021. Because the talk dragged on for a year, shareholders of Sam Chun Dang Pharm are increasingly becoming unhappy about the uncertainty over whether the company will successfully sign a deal with the Chinese firm and when the deal will occur. Another problem is that Sam Chun Dang Pharm released public filings about the licensing deal and other issues. The company posted explanations on a local news report, which said in May last year that the company was discussing a 300 billion won investment with a multinational pharmaceutical company to develop the world’s first oral Covid-19 vaccine. The company has made six filings over the issue until March this year, saying it was developing a Covid-19 vaccine with foreign partners and evaluating its efficacy in global clinical trials. However, the company said it was still in negotiations with partner companies. Repeated clarifications and disclosures could hurt Sam Chun Dang Pharm’s credibility. The company is reportedly working on SCD411, a biosimilar of Eylea, and conducting global phase 3 trials in Korea, the U.S., and Japan. On Tuesday, the stock price of Sam Chung Dang Pharm fell 1.01 percent to 43,950 won.

Tonghua Dongbao Pharmaceutical Investments

1 Investments

Tonghua Dongbao Pharmaceutical has made 1 investments. Their latest investment was in POCTech as part of their Series B on April 4, 2017.

CBI Logo

Tonghua Dongbao Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/14/2017

Series B

POCTech

$14.5M

Yes

4

Date

4/14/2017

Round

Series B

Company

POCTech

Amount

$14.5M

New?

Yes

Co-Investors

Sources

4

Tonghua Dongbao Pharmaceutical Portfolio Exits

3 Portfolio Exits

Tonghua Dongbao Pharmaceutical has 3 portfolio exits. Their latest portfolio exit was POCTech on May 11, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/11/2021

Corporate Majority

$99M

1

6/29/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2011

Shareholder Liquidity

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/11/2021

6/29/2020

3/3/2011

Exit

Corporate Majority

IPO

Shareholder Liquidity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Tonghua Dongbao Pharmaceutical Partners & Customers

2 Partners and customers

Tonghua Dongbao Pharmaceutical has 2 strategic partners and customers. Tonghua Dongbao Pharmaceutical recently partnered with Adocia on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/14/2021

Licensor

France

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

This supply allows Adocia to progress its own BioChaperone ® Lispro and BC programs and expand its partnership opportunities .

3

5/6/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/14/2021

5/6/2016

Type

Licensor

Partner

Business Partner

Country

France

United States

News Snippet

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

This supply allows Adocia to progress its own BioChaperone ® Lispro and BC programs and expand its partnership opportunities .

Subscribe to see more

Subscribe to see more

Sources

3

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.